By Mel J. Yeates

OSE brings CLEC-1 to AACRR

CLEC-1 is a new therapeutic target for immuno-oncology. 
The research program focuses on developing a cancer immunotherapy targeting CLEC-1, a newly identified C-type lectin receptor, to block suppressive functions of myeloid cells and restore antitumor response to T lymphocytes. Suppressive myeloid cells have the ability to accumulate in the tumor microenvironment and deregulate the immune activation of T lymphocytes.
A Network Approach to Target Validation
By Ilene Schneider

A Network Approach to Target Validation

Walter Kolch, co-founder and director of Systems Biology Ireland discusses the merits of a network approach to target validation and why probing clinical samples early is critical to increasing drug development success.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue's Magazine Cover

Latest Issue  

• Volume 16 • Issue 10 • November 2020

November 2020

November 2020 Issue